Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor

Younis Baqi, Ralf Hausmann, Christiane Rosefort, Jürgen Rettinger, Günther Schmalzing, Christa E. Müller

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Evaluation and optimization of anthraquinone derivatives related to Reactive Blue 2 at P2X2 receptors yielded the first potent and selective P2X2 receptor antagonists. The compounds were tested for inhibition of ATP (10 μM) mediated currents in Xenopus oocytes expressing the rat P2X2 receptor. The most potent antagonists were sodium 1-amino-4-[3-(4,6-dichloro[1,3,5]triazine-2- ylamino)phenylamino]- 9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (63, PSB-10211, IC 50 8 6 nM) and disodium 1-amino- 4-[3-(4,6-dichloro[1,3, 5]triazine-2-ylamino)-4-sulfophenylamino]-9,10-dioxo-9,10-dihydroanthracene- 2-sulfonate (57, PSB-1011, IC 50 79 nM). Compound 57 exhibited a competitive mechanism of action (pA 2 7.49). It was >100-fold selective versus P2X4, P2X7, and several investigated P2Y receptor subtypes (P2Y 24612); selectivity versus P2X1 and P2X3 receptors was moderate (>5-fold). Compound 57 was >13-fold more potent at the homomeric P2X2 than at the heteromeric P2X2/3 receptor. Several anthraquinone derivatives were found to act as positive modulators of ATP effects at P2X2 receptors, for example, sodium 1-amino-4-(3-phenoxyphenylamino)-9,10-dioxo-9,10- dihydroanthracene-2-sulfonate (51, PSB-10129, EC 50 489 nM), which led to about a 3-fold increase in the ATP-elicited current.

Original languageEnglish
Pages (from-to)817-830
Number of pages14
JournalJournal of Medicinal Chemistry
Volume54
Issue number3
DOIs
Publication statusPublished - Feb 10 2011

Fingerprint

Purinergic P2X2 Receptors
Anthraquinones
Cibacron Blue F 3GA
Adenosine Triphosphate
Purinergic P2X1 Receptors
Purinergic P2X3 Receptors
Sodium
Triazines
Xenopus
Oocytes

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Baqi, Y., Hausmann, R., Rosefort, C., Rettinger, J., Schmalzing, G., & Müller, C. E. (2011). Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor. Journal of Medicinal Chemistry, 54(3), 817-830. https://doi.org/10.1021/jm1012193

Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor. / Baqi, Younis; Hausmann, Ralf; Rosefort, Christiane; Rettinger, Jürgen; Schmalzing, Günther; Müller, Christa E.

In: Journal of Medicinal Chemistry, Vol. 54, No. 3, 10.02.2011, p. 817-830.

Research output: Contribution to journalArticle

Baqi, Y, Hausmann, R, Rosefort, C, Rettinger, J, Schmalzing, G & Müller, CE 2011, 'Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor', Journal of Medicinal Chemistry, vol. 54, no. 3, pp. 817-830. https://doi.org/10.1021/jm1012193
Baqi, Younis ; Hausmann, Ralf ; Rosefort, Christiane ; Rettinger, Jürgen ; Schmalzing, Günther ; Müller, Christa E. / Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor. In: Journal of Medicinal Chemistry. 2011 ; Vol. 54, No. 3. pp. 817-830.
@article{3b8b0cd95a0a4b1aacd3aabd21105c1f,
title = "Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor",
abstract = "Evaluation and optimization of anthraquinone derivatives related to Reactive Blue 2 at P2X2 receptors yielded the first potent and selective P2X2 receptor antagonists. The compounds were tested for inhibition of ATP (10 μM) mediated currents in Xenopus oocytes expressing the rat P2X2 receptor. The most potent antagonists were sodium 1-amino-4-[3-(4,6-dichloro[1,3,5]triazine-2- ylamino)phenylamino]- 9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (63, PSB-10211, IC 50 8 6 nM) and disodium 1-amino- 4-[3-(4,6-dichloro[1,3, 5]triazine-2-ylamino)-4-sulfophenylamino]-9,10-dioxo-9,10-dihydroanthracene- 2-sulfonate (57, PSB-1011, IC 50 79 nM). Compound 57 exhibited a competitive mechanism of action (pA 2 7.49). It was >100-fold selective versus P2X4, P2X7, and several investigated P2Y receptor subtypes (P2Y 24612); selectivity versus P2X1 and P2X3 receptors was moderate (>5-fold). Compound 57 was >13-fold more potent at the homomeric P2X2 than at the heteromeric P2X2/3 receptor. Several anthraquinone derivatives were found to act as positive modulators of ATP effects at P2X2 receptors, for example, sodium 1-amino-4-(3-phenoxyphenylamino)-9,10-dioxo-9,10- dihydroanthracene-2-sulfonate (51, PSB-10129, EC 50 489 nM), which led to about a 3-fold increase in the ATP-elicited current.",
author = "Younis Baqi and Ralf Hausmann and Christiane Rosefort and J{\"u}rgen Rettinger and G{\"u}nther Schmalzing and M{\"u}ller, {Christa E.}",
year = "2011",
month = "2",
day = "10",
doi = "10.1021/jm1012193",
language = "English",
volume = "54",
pages = "817--830",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor

AU - Baqi, Younis

AU - Hausmann, Ralf

AU - Rosefort, Christiane

AU - Rettinger, Jürgen

AU - Schmalzing, Günther

AU - Müller, Christa E.

PY - 2011/2/10

Y1 - 2011/2/10

N2 - Evaluation and optimization of anthraquinone derivatives related to Reactive Blue 2 at P2X2 receptors yielded the first potent and selective P2X2 receptor antagonists. The compounds were tested for inhibition of ATP (10 μM) mediated currents in Xenopus oocytes expressing the rat P2X2 receptor. The most potent antagonists were sodium 1-amino-4-[3-(4,6-dichloro[1,3,5]triazine-2- ylamino)phenylamino]- 9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (63, PSB-10211, IC 50 8 6 nM) and disodium 1-amino- 4-[3-(4,6-dichloro[1,3, 5]triazine-2-ylamino)-4-sulfophenylamino]-9,10-dioxo-9,10-dihydroanthracene- 2-sulfonate (57, PSB-1011, IC 50 79 nM). Compound 57 exhibited a competitive mechanism of action (pA 2 7.49). It was >100-fold selective versus P2X4, P2X7, and several investigated P2Y receptor subtypes (P2Y 24612); selectivity versus P2X1 and P2X3 receptors was moderate (>5-fold). Compound 57 was >13-fold more potent at the homomeric P2X2 than at the heteromeric P2X2/3 receptor. Several anthraquinone derivatives were found to act as positive modulators of ATP effects at P2X2 receptors, for example, sodium 1-amino-4-(3-phenoxyphenylamino)-9,10-dioxo-9,10- dihydroanthracene-2-sulfonate (51, PSB-10129, EC 50 489 nM), which led to about a 3-fold increase in the ATP-elicited current.

AB - Evaluation and optimization of anthraquinone derivatives related to Reactive Blue 2 at P2X2 receptors yielded the first potent and selective P2X2 receptor antagonists. The compounds were tested for inhibition of ATP (10 μM) mediated currents in Xenopus oocytes expressing the rat P2X2 receptor. The most potent antagonists were sodium 1-amino-4-[3-(4,6-dichloro[1,3,5]triazine-2- ylamino)phenylamino]- 9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (63, PSB-10211, IC 50 8 6 nM) and disodium 1-amino- 4-[3-(4,6-dichloro[1,3, 5]triazine-2-ylamino)-4-sulfophenylamino]-9,10-dioxo-9,10-dihydroanthracene- 2-sulfonate (57, PSB-1011, IC 50 79 nM). Compound 57 exhibited a competitive mechanism of action (pA 2 7.49). It was >100-fold selective versus P2X4, P2X7, and several investigated P2Y receptor subtypes (P2Y 24612); selectivity versus P2X1 and P2X3 receptors was moderate (>5-fold). Compound 57 was >13-fold more potent at the homomeric P2X2 than at the heteromeric P2X2/3 receptor. Several anthraquinone derivatives were found to act as positive modulators of ATP effects at P2X2 receptors, for example, sodium 1-amino-4-(3-phenoxyphenylamino)-9,10-dioxo-9,10- dihydroanthracene-2-sulfonate (51, PSB-10129, EC 50 489 nM), which led to about a 3-fold increase in the ATP-elicited current.

UR - http://www.scopus.com/inward/record.url?scp=79851471254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79851471254&partnerID=8YFLogxK

U2 - 10.1021/jm1012193

DO - 10.1021/jm1012193

M3 - Article

C2 - 21207957

AN - SCOPUS:79851471254

VL - 54

SP - 817

EP - 830

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 3

ER -